Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - atazanavir sulfate, quantity: 227.79 mg (equivalent: atazanavir, qty 200 mg) - capsule, hard - excipient ingredients: magnesium stearate; lactose monohydrate; crospovidone; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; pharmaceutical glaze; dimeticone; indigo carmine; potable water; gelatin; sodium lauryl sulfate - reyataz is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see 5.1 pharmacodynamic properties: clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - atazanavir sulfate -

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - nivolumab, quantity: 255.6 mg; relatlimab, quantity: 85.2 mg - injection, concentrated - excipient ingredients: histidine hydrochloride monohydrate; water for injections; pentetic acid; sucrose; polysorbate 80; histidine - opdualag is indicated for the treatment of patients with unresectable or metastatic melanoma who are at least 12 years old.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - mavacamten, quantity: 5 mg - capsule, hard - excipient ingredients: magnesium stearate; hypromellose; croscarmellose sodium; gelatin; silicon dioxide; iron oxide yellow; mannitol; titanium dioxide; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - camzyos is indicated for the treatment of adults with symptomatic nyha class ii-iii obstructive hypertrophic cardiomyopathy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - mavacamten, quantity: 2.5 mg - capsule, hard - excipient ingredients: magnesium stearate; hypromellose; croscarmellose sodium; gelatin; silicon dioxide; iron oxide black; mannitol; titanium dioxide; iron oxide red; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide - camzyos is indicated for the treatment of adults with symptomatic nyha class ii-iii obstructive hypertrophic cardiomyopathy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - mavacamten, quantity: 15 mg - capsule, hard - excipient ingredients: magnesium stearate; hypromellose; croscarmellose sodium; gelatin; silicon dioxide; iron oxide black; mannitol; titanium dioxide; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide - camzyos is indicated for the treatment of adults with symptomatic nyha class ii-iii obstructive hypertrophic cardiomyopathy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - mavacamten, quantity: 10 mg - capsule, hard - excipient ingredients: magnesium stearate; hypromellose; croscarmellose sodium; gelatin; silicon dioxide; iron oxide red; mannitol; titanium dioxide; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - camzyos is indicated for the treatment of adults with symptomatic nyha class ii-iii obstructive hypertrophic cardiomyopathy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - elotuzumab, quantity: 440 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; citric acid monohydrate; sucrose; polysorbate 80; water for injections - empliciti (elotuzumab) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - elotuzumab, quantity: 340 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; citric acid monohydrate; sucrose; polysorbate 80; water for injections - empliciti (elotuzumab) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - daclatasvir dihydrochloride -